Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Molecular Therapy. Methods & Clinical Development
|
December 14, 2023
Erratum: Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
John R Lydeard, Michelle I Lin, Huanying Gary Ge, et al.
Molecular Therapy. Methods & Clinical Development
|
November 29, 2023
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
John R Lydeard, Michelle I Lin, Huanying Gary Ge, et al.
Iscience
|
April 10, 2026
A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity
Matthew Ung, Julia Etchin, Amanda Halfond, et al.
Nature Medicine
|
May 12, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
John F DiPersio, Guenther Koehne, Nirali N Shah, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Molecular Therapy. Methods & Clinical Development
|
December 14, 2023
Erratum: Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
John R Lydeard, Michelle I Lin, Huanying Gary Ge, et al.
Molecular Therapy. Methods & Clinical Development
|
November 29, 2023
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
John R Lydeard, Michelle I Lin, Huanying Gary Ge, et al.
Iscience
|
April 10, 2026
A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity
Matthew Ung, Julia Etchin, Amanda Halfond, et al.
Nature Medicine
|
May 12, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
John F DiPersio, Guenther Koehne, Nirali N Shah, et al.
Page
of 2